129 related articles for article (PubMed ID: 29516155)
21. Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM; Zoernig I; Hassel JC; Halama N; Dick J; Lang N; Podola L; Funk J; Ziegelmeier C; Juenger S; Bucur M; Umansky L; Falk CS; Freitag A; Karapanagiotou-Schenkel I; Beckhove P; Enk A; Jaeger D
Eur J Cancer; 2018 Feb; 90():122-129. PubMed ID: 29306769
[TBL] [Abstract][Full Text] [Related]
22. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
[TBL] [Abstract][Full Text] [Related]
23. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Ribas A; Hamid O; Daud A; Hodi FS; Wolchok JD; Kefford R; Joshua AM; Patnaik A; Hwu WJ; Weber JS; Gangadhar TC; Hersey P; Dronca R; Joseph RW; Zarour H; Chmielowski B; Lawrence DP; Algazi A; Rizvi NA; Hoffner B; Mateus C; Gergich K; Lindia JA; Giannotti M; Li XN; Ebbinghaus S; Kang SP; Robert C
JAMA; 2016 Apr; 315(15):1600-9. PubMed ID: 27092830
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of diffuse large B-cell lymphoma: Impact of biosimilar rituximab and radiation.
Ganesan P; Sagar TG; Kannan K; Radhakrishnan V; Rajaraman S; John A; Sundersingh S; Mahajan V; Ganesan TS
Indian J Cancer; 2017; 54(2):430-435. PubMed ID: 29469072
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.
Glitza IC; Guha-Thakurta N; D'Souza NM; Amaria RN; McGovern SL; Rao G; Li J
Melanoma Res; 2017 Dec; 27(6):580-584. PubMed ID: 28817446
[TBL] [Abstract][Full Text] [Related]
26. Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: results of a retrospective single-institution cohort study.
Ibrahim T; Mateus C; Baz M; Robert C
Cancer Immunol Immunother; 2018 Oct; 67(10):1571-1578. PubMed ID: 30056599
[TBL] [Abstract][Full Text] [Related]
27. Local Tumor Treatment in Combination with Systemic Ipilimumab Immunotherapy Prolongs Overall Survival in Patients with Advanced Malignant Melanoma.
Theurich S; Rothschild SI; Hoffmann M; Fabri M; Sommer A; Garcia-Marquez M; Thelen M; Schill C; Merki R; Schmid T; Koeberle D; Zippelius A; Baues C; Mauch C; Tigges C; Kreuter A; Borggrefe J; von Bergwelt-Baildon M; Schlaak M
Cancer Immunol Res; 2016 Sep; 4(9):744-54. PubMed ID: 27466265
[TBL] [Abstract][Full Text] [Related]
28. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS
Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151
[TBL] [Abstract][Full Text] [Related]
29. Circulating Tumour DNA for Monitoring Treatment Response to Anti-PD-1 Immunotherapy in Melanoma Patients.
Ashida A; Sakaizawa K; Uhara H; Okuyama R
Acta Derm Venereol; 2017 Nov; 97(10):1212-1218. PubMed ID: 28681063
[TBL] [Abstract][Full Text] [Related]
30. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
[TBL] [Abstract][Full Text] [Related]
31. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Weber JS; D'Angelo SP; Minor D; Hodi FS; Gutzmer R; Neyns B; Hoeller C; Khushalani NI; Miller WH; Lao CD; Linette GP; Thomas L; Lorigan P; Grossmann KF; Hassel JC; Maio M; Sznol M; Ascierto PA; Mohr P; Chmielowski B; Bryce A; Svane IM; Grob JJ; Krackhardt AM; Horak C; Lambert A; Yang AS; Larkin J
Lancet Oncol; 2015 Apr; 16(4):375-84. PubMed ID: 25795410
[TBL] [Abstract][Full Text] [Related]
32. Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders.
Tudesq JJ; Cartron G; Rivière S; Morquin D; Iordache L; Mahr A; Pourcher V; Klouche K; Cerutti D; Le Quellec A; Guilpain P
Autoimmun Rev; 2018 Feb; 17(2):115-124. PubMed ID: 29180125
[TBL] [Abstract][Full Text] [Related]
33. Rituximab Maintenance Strategy in Advanced Follicular Lymphoma: Facts and Controversies.
Milunović V; Bogeljić Patekar M; Jakubac KM; Mandac Rogulj I; Radić-Krišto D; Planinc-Peraica A; Ostojić Kolonić S
Acta Clin Croat; 2017 Mar; 56(1):143-156. PubMed ID: 29120553
[TBL] [Abstract][Full Text] [Related]
34. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
Markovic SN; Geyer SM; Dawkins F; Sharfman W; Albertini M; Maples W; Fracasso PM; Fitch T; Lorusso P; Adjei AA; Erlichman C
Cancer; 2005 Jun; 103(12):2584-9. PubMed ID: 15887220
[TBL] [Abstract][Full Text] [Related]
35. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma.
Epperla N; Ahn KW; Ahmed S; Jagasia M; DiGilio A; Devine SM; Jaglowski S; Kennedy V; Rezvani AR; Smith SM; Sureda A; Fenske TS; Kharfan-Dabaja MA; Armand P; Hamadani M
J Hematol Oncol; 2017 Jun; 10(1):117. PubMed ID: 28606176
[TBL] [Abstract][Full Text] [Related]
36. Description of late onset neutropenia in indolent lymphoma patients treated with bendamustine plus rituximab.
Verriere B; Gastaud L; Chamorey E; Peyrade F; Deletie E; Bouredji K; Quinsat D; Schiappa R; Thyss A; Re D
Hematol Oncol; 2018 Feb; 36(1):144-149. PubMed ID: 28685846
[TBL] [Abstract][Full Text] [Related]
37. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
38. Low-dose rituximab as an adjuvant therapy in pemphigus.
Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
[TBL] [Abstract][Full Text] [Related]
39. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
Hainsworth JD; Infante JR; Spigel DR; Peyton JD; Thompson DS; Lane CM; Clark BL; Rubin MS; Trent DF; Burris HA
Cancer; 2010 Sep; 116(17):4122-9. PubMed ID: 20564157
[TBL] [Abstract][Full Text] [Related]
40. [Combination strategies in melanoma therapy.].
Spagnolo F
Recenti Prog Med; 2017 Dec; 108(12):503-507. PubMed ID: 29297899
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
